Siguazodan (SKF 94836) is a potent, selective, and orally active phosphodiesterase III (PDE-III) inhibitor used for its antiplatelet, positive inotropic, and vasodilatory effects; it increases cAMP accumulation in platelets, inhibits platelet aggregation induced by U46619, and suppresses phenylephrine-induced 5-HT release.